Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Advances in paediatric cancer treatment.

Saletta F, Seng MS, Lau LM.

Transl Pediatr. 2014 Apr;3(2):156-82. doi: 10.3978/j.issn.2224-4336.2014.02.01. Review.

2.

Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.

Bradley KA, Zhou T, McNall-Knapp RY, Jakacki RI, Levy AS, Vezina G, Pollack IF.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e55-60. doi: 10.1016/j.ijrobp.2012.09.004. Epub 2012 Oct 22.

3.

Neurotoxicity of biologically targeted agents in pediatric cancer trials.

Wells EM, Nageswara Rao AA, Scafidi J, Packer RJ.

Pediatr Neurol. 2012 Apr;46(4):212-21. doi: 10.1016/j.pediatrneurol.2012.02.006. Review.

4.

Genomic aberrations in pediatric diffuse intrinsic pontine gliomas.

Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS.

Neuro Oncol. 2012 Mar;14(3):326-32. doi: 10.1093/neuonc/nor190. Epub 2011 Nov 7.

5.

Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.

Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ.

J Clin Oncol. 2011 Oct 20;29(30):3999-4006. doi: 10.1200/JCO.2011.35.5677. Epub 2011 Sep 19.

6.

Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.

Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE.

Neuro Oncol. 2011 Mar;13(3):298-306. doi: 10.1093/neuonc/noq202.

7.

Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.

Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW.

J Neurooncol. 2011 Aug;104(1):179-89. doi: 10.1007/s11060-010-0502-4. Epub 2011 Jan 19.

8.

DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.

Prabhu SP, Ng S, Vajapeyam S, Kieran MW, Pollack IF, Geyer R, Haas-Kogan D, Boyett JM, Kun L, Poussaint TY.

Childs Nerv Syst. 2011 Jan;27(1):11-8. doi: 10.1007/s00381-010-1323-7. Epub 2010 Nov 4.

9.

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.

Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, Pai Panandiker AS, Leung W, Chin TK, Stewart CF, Kocak M, Rowland C, Merchant TE, Kaste SC, Gajjar A.

J Clin Oncol. 2010 Nov 1;28(31):4762-8. doi: 10.1200/JCO.2010.30.3545. Epub 2010 Oct 4. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5351. Panandiker, Atmaram Pai [corrected to Pai Panandiker, Atmaram S].

10.

Targeted therapy in the treatment of malignant gliomas.

Lukas RV, Boire A, Nicholas MK.

Onco Targets Ther. 2009 Feb 18;2:115-33.

12.

Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

Rahman R, Smith S, Rahman C, Grundy R.

J Oncol. 2010;2010:251231. doi: 10.1155/2010/251231. Epub 2010 Apr 11.

13.

Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Mueller S, Chang S.

Neurotherapeutics. 2009 Jul;6(3):570-86. doi: 10.1016/j.nurt.2009.04.006. Review.

Supplemental Content

Support Center